On July 19, 2024, Hipo Pharmaceutical-B (02142) issued a profit warning, forecasting an unaudited surplus for the six months ending June 30, 2024 to be between 1 million and 1.5 million US dollars, a decrease from the 2.9 million US dollars in the same period in 2023. The company stated that the decrease in surplus is mainly due to changes in revenue structure, with an increase in service business revenue proportion but lower profit margin. Nevertheless, the company emphasized its stable and diversified sources of income, and obtained important milestone payments during the reporting period. At the same time, new licensing and cooperative relationships, as well as cost control strategies, will help to maintain overall surplus. The company will announce detailed mid-term performance by the end of August 2024.

On July 19, 2024, Hipo Pharmaceutical-B (02142) issued a profit warning, forecasting an unaudited surplus for the six months ending June 30, 2024 to be between 1 million and 1.5 million US dollars, a decrease from the 2.9 million US dollars in the same period in 2023. The company stated that the decrease in surplus is mainly due to changes in revenue structure, with an increase in service business revenue proportion but lower profit margin. Nevertheless, the company emphasized its stable and diversified sources of income, and obtained important milestone payments during the reporting period. At the same time, new licensing and cooperative relationships, as well as cost control strategies, will help to maintain overall surplus. The company will announce detailed mid-term performance by the end of August 2024.